Toll Free: 1-888-928-9744

Angiogenesis Modulators

Published: Apr, 2015 | Pages: 1449 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)

This report on Angiogenesis Modulators & Therapeutics studies the impact of Inhibitors and Stimulators on various diseases. The study focuses on major angiogenesis inhibitors and their role in diseases such as cancer, cardiology, ophthalmology, and other angiogenesis based diseases including endometriosis and inflammatory diseases. The emphasis is also given on major angiogenesis stimulators and their role in diseases such as cardiovascular disorders including ischemia, congestive heart failure, coronary artery disease, myocardial infarction and peripheral vascular disease and chronic wound care. The study provides global market analysis for angiogenesis therapeutic products by the above angiogenesis modulators and also by the disease areas such as cancer, cardiovascular disorders and other angiogenesis based diseases. Compilation of Worldwide Patents and Research related to Angiogenesis is also provided. The study includes estimations and predictions for the total global angiogenesis therapeutic products market. Estimations and predictions are also graphically illustrated by geographic regions encompassing the North America, Europe, Asia-Pacific and Rest of World.
 Table of Content
1. SCOPE AND METHODOLOGY	1
2. REPORT SYNOPSIS	3
2.1 Introduction	3
Angiogenesis	3
Exhibit 1. Segmentation of Global Angiogenesis Modulators Market by Angiogenesis Modulators and Therapeutic Area	3
Exhibit 2. Segmentation of Global Angiogenesis Therapeutic Products for Cancer Market by Type	3
Angiogenesis Modulators	4
Angiogenesis Inhibitors	4
Mode of Action	5
Blocking of VEGF Pathway	5
Angiogenesis Stimulators	5
Angiogenesis – Therapeutic Areas	6
Cancer	6
Cancer	6
Thalomid and lenalidomide (Revlimid) are some other drugs that are used in cancer therapy and these have affect on growth of blood vessels. These have affect on cancer in other ways as well.	6
Cardiovascular	6
Mechanical Therapy for Stimulating Angiogenesis	7
TMR	7
EECP	7
Ophthalmology	7
Other Diseases	8
Endometriosis	8
Rheumatology	8
Wound Healing	8
Dermatology	9
2.2 Angiogenesis Modulators - Global Market Analysis	10
Exhibit 3. Angiogenesis Modulators - Global Market Estimations & Predictions (2005 -2020) in US$ Million	10
Exhibit 4. List of Major Global Companies in Angiogenesis Modulators Market	11
3. MARKET DYNAMICS	12
3.1 Market Overview	12
Global Market Analysis	12
3.2 Global Angiogenesis Modulators Market	13
Exhibit 5. Angiogenesis Modulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	13
Exhibit 6. Angiogenesis Modulators – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	14
3.3 North American Angiogenesis Modulators Market	15
Exhibit 7. Angiogenesis Modulators – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million	15
Exhibit 8. Angiogenesis Modulators – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada	16
Exhibit 9. List of Major Companies in North America	16
3.3 (I) United States Angiogenesis Modulators Market	16
3.3 (II) Canadian Angiogenesis Modulators Market	16
Exhibit 10. List of Approved Angiogenesis based Drugs in the United States	17
3.4 European Angiogenesis Modulators Market	20
Exhibit 11. Angiogenesis Modulators - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million	20
Exhibit 12. Angiogenesis Modulators – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe	21
3.4 (I) German Angiogenesis Modulators Market	21
3.4 (II) UK Angiogenesis Modulators Market	21
3.4 (III) French Angiogenesis Modulators Market	21
3.4 (IV) Swiss Angiogenesis Modulators Market	21
3.4 (V) Russian Angiogenesis Modulators Market	21
Exhibit 13. List of Major European Companies in Angiogenesis Modulators Market	22
Exhibit 14. List of Approved Angiogenesis based Drugs in Europe	22
3.5 Asia-Pacific Angiogenesis Modulators Market	25
Exhibit 15. Angiogenesis Modulators - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million	25
Exhibit 16. Angiogenesis Modulators – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific	26
3.5 (I) Japanese Angiogenesis Modulators Market	26
3.5 (II) Chinese Angiogenesis Modulators Market	26
3.5 (III) Australian Angiogenesis Modulators Market	26
3.5 (IV) Indian Angiogenesis Modulators Market	26
Exhibit 17. List of Major Asia-Pacific Companies in Angiogenesis Modulators Market	26
3.6 Rest of World Angiogenesis Modulators Market	27
Exhibit 18. Angiogenesis Modulators - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other Countries in US$ Million	27
Exhibit 19. Angiogenesis Modulators – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other	28
3.6 (I) Brazilian Angiogenesis Modulators Market	28
3.6 (II) South African Angiogenesis Modulators Market	28
3.6 (III) Israeli Angiogenesis Modulators Market	28
3.7 Company Profiles - Major Players in Angiogenesis Market	29
Amgen, Inc. (USA)	29
AstraZeneca plc (UK)	29
Bayer Pharma AG (Germany)	30
Bionomics Ltd. (Australia)	32
CASI Pharmaceuticals, Inc. (USA)	33
Celgene Corporation (USA)	35
Eisai Co., Ltd. (Japan)	35
Eli Lilly and Company (USA)	37
F.Hoffmann-La Roche Ltd. (Switzerland)	37
Genentech, Inc. (USA)	38
GlaxoSmithKline plc (UK)	40
KCI Licensing, Inc. (USA)	41
Merck KGaA (Germany)	42
Novartis AG (Switzerland)	42
OHR Pharmaceuticals (USA)	45
Organogenesis, Inc. (USA)	45
Pfizer, Inc. (USA)	46
Progen Pharmaceuticals Ltd. (Australia)	47
Regeneron Pharmaceuticals, Inc. (USA)	48
Sanofi SA (France)	49
Silence Therapeutics plc (UK)	50
Smith & Nephew plc (UK)	51
Takeda Pharmaceutical Co., Ltd. (Japan)	52
Taxus Cardium Pharmaceuticals Group (USA)	53
Vical, Inc. (USA)	54
3.8 Major Activities in Angiogenesis Market	55
Bayer Yakuhin’s Aflibercept Receives Approval in Japan for Application in Myopic CNV Treatment	55
Antitope and UCL Enters into Collaboration for an Important Antibody	55
FDA Approves Avastin for Cervical Cancer	55
Indian-American Scientist to Launch Wound-Healing Products in India	56
Investigational Monoclonal Antibody OS2966 of OncoSynergy Granted Orphan Drug Status by the FDA to Treat Glioblastoma	56
US Patent Office Grants McCord Research Endothelial Cell Treatment Patent	57
Nexavar® (sorafenib) Approved to Treat Differentiated Thyroid Cancer in Japan	57
Duke Cancer Institute, UNC and WUSTL Team Up to Accelerate Oncology Drug Development	58
US FDA Approves First Targeted Drug for Advanced Stomach Cancer	58
Effective New Peptide Developed to Treat Ulcer and Wound	59
TRACON and Santen Enters into Agreement to Develop and Commercialize TRC105 in Ophthalmology	59
Strategic Collaboration between Bayer & German Cancer Research Center (DKFZ) Against Cancer	59
Pfizer and Merck Enters into Collaboration to Study Innovative Anti-Cancer Combinations	60
Eddingpharm Acquires Worldwide Rights to Oncology Assets, Inclusive of Telatinib, from ACT Biotech	60
ARIAD Enters into Commercialization Agreement for Iclusig (Ponatinib) in Australia	61
Ethical Oncology Science (EOS) Acquired by Clovis Oncology; Obtains Rights to Lucitanib, a Unique Dual-Selective Phase II FGFR/VEGFR Inhibitor	61
Clovis Oncology to Partner with Servier	61
Avastin Receives Approval for Additional Indication of Ovarian Cancer	62
USPTO Issues Notice of Allowance to Patent Extensive Cancer Diagnostic Applications of MIR-21	62
MedImmune Acquires Amplimmune	62
BI Submits MAA for EU Approval of New Oncology Compound, Nintedanib	63
Servier and Shanghai Institute of Materia Medica Join Hands	63
AstraZeneca Teams Up with Cambridge Medical Research Institutions to Advance Cancer Research	64
ENMD Submits an Application for New Drug Global Clinical Trial for the Proprietary ENMD-2076 with CFDA of China	64
Avastin Receives Approval for Additional Indication of Malignant Glioma	64
Phase III Clinical Trial of Regorafenib Initiated	64
EntreMed Gains Patent for ENMD-2076 in China	65
Exelixis to Commence METEOR Clinical Trial for Cabozantinib in mRCC Patients	65
ArQule Recovers Global Rights to AKT Program	66
Exelixis Inks a 3-Year Supply Agreement with Sobi for the Distribution of COMETRIQ for MTC in the EU	66
Stivarga Receives FDA Approval for Metastatic GIST	66
Exelixis Markets COMETRIQ™ in the US	67
EntreMed Finalizes the Site for Phase 2 studies in TNBC	67
Genentech’s Avastin® with Chemotherapy Gain US FDA Approval for Application for mCRC Treatment	68
COMETRIQ™ Attains FDA Approval for Therapeutic Application in MTC	68
AnGes MG Receives Medical Use Patent for HGF in Japan	68
ArQule Along with Daiichi Sankyo Inks a SPA Agreement	69
Ethical Oncology Science Collaborates with Servier	69
Dyax Inks a Licensing Agreement with Kadmon	70
Abcam Acquires Epitomics, Known for RabMAb® Technology	70
AnGes and Mitsubishi Tanabe Pharma Enters into Agreement for Exclusive Marketing Rights of Collategene in the United States	70
BioInvent Enters into Oncology Collaboration with Cancer Research Technology	71
BioInvent Together with ThromboGenics to Acquire Complete Rights to TB-403	71
European Commission Accepts CAPRELSA (vandetanib) for Patients with Advanced Medullary Thyroid Cancer	71
Pfizer’s INLYTA® (Axitinib) Receives FDA Approval for Advanced Renal Cell Carcinoma (RCC)	72
BioLineRx Collaborates with Compugen to Enhance and Market the Innovative Drug Candidates of Compugen	72
Teva Merges with Cephalon	73
Bayer HealthCare Restructures Global Oncology Partnership with Onyx Pharmaceuticals to Settle Litigation	73
Lorus Therapeutics Receives Australian Patent for the Anti-Cancer Drug LOR-253	73
SuperGen Inc., Renamed as Astex Pharmaceuticals Inc.,	74
Medical-Use Patent for Ets-1 in the US	74
SuperGen Acquires Astex Therapeutics	74
IBC Generium In-Licenses New Anti‐VEGF Antibody Drug from Affitech A/S	75
Capstone Therapeutics and BiolineRx Plans to Co-Develop a Chrysalin (TP508) based Drug	75
Quest Diagnostics Takes Over Celera	75
Abcam Acquires MitoSciences to Enhance Immunoassay Portfolio	75
Sanofi-Aventis Completely Acquires Genzyme Corporation	76
Alcon Completely Merges with Novartis, Creating a New Eye Care Division	76
Regulus Therapeutics and UC San Diego to utilize microRNA Technology in Angiogenic Disease Research Collaboration	76
Human Genome Sciences and Fiveprime Therapeutics Collaborates to Develop and Market New Anti-Cancer Drug	77
Arteriocyte Launches NANEX™ Stem Cell Expansion System	77
Hana Biosciences Renamed as Talon Therapeutics	77
Eyetech Initiates the Development of Extended Release Formulation of Macugen	78
Biotica Reports a Unique Molecular Target of Bioengineered Borrelidin Analogues	78
Ethical Oncology Science Initiates Phase I Clinical Trials of E-3810	78
Gilead Sciences Acquires CGI Pharmaceuticals for US$ 120 Million	79
Sanofi-Aventis Acquires TargeGen	79
FDA Approves Lucentis for Macular Edema following Retinal Vein Occlusion	79
Progen Pharmaceuticals and Medigen Biotech Corp., Enters into a License and Collaboration Agreement	80
ACT Biotech Obtains Orphan Drug Designation for Telatinib for Gastric Cancer	80
TRACON Initiates TRC 105 Antibody Therapy for Prostate Cancer	81
FDA Grants Orphan Drug Status to ENMD-2076 in Leukemia	81
Votrient Receives FDA Approval	81
PolyMedix Receives US Patent for Angiogenesis Inhibitor Compounds	81
Lilly Acquires ImClone Systems	82
FDA Grants Orphan Drug Status to VEGFb™ Intended to be Used Against Advanced Melanoma	82
Nexavar® First FDA-Approved Drug Therapy for Liver Cancer	82
Bionomics’ Anti-Cancer Compound Gains IND Approval	83
Bilateral Agreement for Product Distribution between Cell Culture Service and TCS Cellworks Limited	83
Coley Agrees to Acquisition by Pfizer	84
Chugai Achieves Japanese Regulatory Approval for Tarceva® for NSCLC Treatment	84
Synta Pharmaceuticals and GSK to Jointly Develop STA-4783	84
Atrium Biotechnologies Inc. will Become Atrium Innovations, Inc.	85
ARIAD Announces Collaboration with ICON Medical to Develop and Commercialize Novel Deforolimus-Eluting Stents	85
Bristol-Myers Squibb Acquires Adnexus Therapeutics	85
Celera Enters Oncology Research Collaboration with Merck to Develop Pharmacogenomic Tests	86
Avastin® and Chemotherapy Combination as First-line Treatment for NSCLC Approved in Europe	86
Genentech Acquires Tanox	87
System Medicine, Now a Wholly Owned Subsidiary of Cell Therapeutics, Inc	87
ARIAD and Merck & Co., Inc. Announce Global Collaboration to Jointly Develop and Commercialize AP23573 - ARIAD's Novel mTOR Inhibitor - for Cancer	87
Valentis and Urigen Merge	88
National Cancer Institute Selects SR 16388 of SRI International	88
Abbott and Genentech Announce Global, Integrated Research, Development and Commercialization Collaboration in Oncology	88
Strategic Alliance Between Merck and Archemix	89
Progen Industries is now Progen Pharmaceuticals	89
Chugai Pharmaceutical Obtains Approval for Avastin® in Japan	89
Eisai Corporation Concludes the Deal to Acquire Morphotek, Inc	90
Celera and LabCorp® Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays	90
Paradigm Therapeutics Acquired by Takeda Pharmaceutical	90
ARIAD Grants Second Commercial License to its Patented ARGENT(TM) Cell-Signaling Regulation Technology for Development of New Cancer Therapies	91
University of Bristol Awards Drug Discovery Contract to Galapagos NV	91
ImClone Systems Decides to Focus on its Proprietary Product, IMC-1121B	91
AngioGenetics Discovers New Mechanism for Blood Vessel Growth	92
Seattle Genetics in Exclusive Worldwide Licensing Agreement with Genentech for SGN-40	92
Celgene Acquires API Unit from Siegfried Ltd.	92
Otsuka and Chugai in Co-Promotion Deal	93
Merck Buys Entire Stake in Sirna Therapeutics	93
Genetix Acquires Applied Imaging Corporation	93
InterMune and Roche Close Collaboration Agreement	93
EntreMed Presents 2ME2 for Rheumatoid Arthritis	94
Genzyme Acquires AnorMED	94
Biomira Acquires ProlX Pharmaceuticals	94
Pfizer Acquires PowderMed	94
CTT Cancer Targeting Technologies and Karyon Ltd., Merge	94
LibraGen and Sanofi-Aventis in Partnership for Microbial Diversity Applications	94
Schering and Sonus Sign Global Licensing Agreement for TOCOSOL(R) Paclitaxel	95
Merck Acquires Serono	95
Sangamo Acquires Edwards' Angiogenesis Program	95
AstraZeneca Acquires Cambridge Antibody Technology	95
GSK and Shionogi Complete Initial Clinical Study for HIV Integrase Inhibitor	95
Cardium Acquires Wound Healing Technology and Related Assets of TRC	96
GSK and Galapagos Enter Into an Alliance for Osteoarthritis Drug Development	96
Caliper Acquires Xenogen	96
Pharmacopeia and Allergan Inc., in AMD Research Agreement	96
Angiotech Pharmaceuticals Acquires Quill Medical Inc.	96
Mayne Acquires SuperGen's North American Rights for Oncology Products	96
Erbitux ® Approved in the US	97
Corgentech Adopts New Name	97
Angiotech and Genzyme Enter Into Strategic Collaboration for Developing Oncology Treatments	97
Alcon and Amgen for Joint Development of Ophthalmology Therapies	97
CancerVax Merges with Micromet	97
Microbix and Angiogen Enter Into Marketing Agreement	97
SuperGen Acquires Montigen	98
Novartis Takes Over Chiron	98
Amgen Completes Acquisition of Abgenix	98
Æterna Zentaris’ Development of Cetrorelix to Continue in Japan	98
Corautus Genetics Puts Forth VEGF-2 Studies	98
Angiotech Pharmaceuticals Takes Over American Medical Instruments	99
Amgen and Biovitrum in License Agreement	99
Cryptome Takes Over HealthLinx	99
AngioGenex Merges with eClic	99
Merck Acquires Full US Rights to BLP25 Liposome Vaccine from Biomira	99
Human Genome Science and Amgen in Licensing Agreement	99
Protein Design Labs Changes Corporate Identity	100
Bausch & Lomb and PTC Therapeutics in Research Collaboration Deal	100
Sanofi-Aventis and Regeneron Pharmaceuticals Amend VEGF Collaboration	100
OSI Pharmaceuticals Acquires Eyetech Pharmaceuticals	100
Hybridon Adopts New Name	100
Xencor and Centocor Enter into Monoclonal Antibodies Agreement	100
Corautus in Diabetic Neuropathy Licensing Agreement	101
Xantos and Cryptome Sign Agreement to Validate Cancer Leads	101
Xantos and Atugen Sign Collaboration Agreement	101
Allergan and Sanwa Kagaku Kenkyusho Develop Posurdex in Japan	101
Corautus and Boehringer Ingelheim Sign Agreement to Produce VEGF-2	101
Bayer and Onyx Announce Access to Sorafenib (BAY 43-9006)	102
7TM Signs Therapeutic Angiogenesis Research Agreement with P&G	102
Genzyme Acquires Verigen	102
Antisoma and Raylo Sign Agreement for Manufacturing AS1411	102
Alcon and Morphochem Enter Into Alliance for Ophthalmic Compounds	102
ImClone Systems Signs License Agreements	103
Pfizer Takes Over Angiosyn	103
3.9 Analysis by Modulators	104
Exhibit 20. Angiogenesis Modulators – Global Market Estimations & Predictions (2005 - 2020) by Angiogenesis Modulators for Inhibitors and Stimulators in US$ Million	104
Exhibit 21. Angiogenesis Modulators – Global Market Shares (2010, 2015 & 2020) by Angiogenesis Modulators for Inhibitors and Stimulators	105
3.9.1 Angiogenesis Inhibitors	106
3.9.1.1 Global Angiogenesis Inhibitors Market	106
Exhibit 22. Angiogenesis Inhibitors - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	107
Exhibit 23. Angiogenesis Inhibitors – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	108
3.9.1.2 North American Angiogenesis Inhibitors Market	109
Exhibit 24. Angiogenesis Inhibitors – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million	109
Exhibit 25. Angiogenesis Inhibitors – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada	110
3.9.1.2 (I) United States Angiogenesis Inhibitors Market	110
3.9.1.2 (II) Canadian Angiogenesis Inhibitors Market	110
3.9.1.3 European Angiogenesis Inhibitors Market	111
Exhibit 26. Angiogenesis Inhibitors - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million	111
Exhibit 27. Angiogenesis Inhibitors – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe	112
3.9.1.3 (I) German Angiogenesis Inhibitors Market	112
3.9.1.3 (II) UK Angiogenesis Inhibitors Market	112
3.9.1.3 (III) French Angiogenesis Inhibitors Market	112
3.9.1.3 (IV) Swiss Angiogenesis Inhibitors Market	112
3.9.1.3 (V) Russia Angiogenesis Inhibitors Market	112
3.9.1.4 Asia-Pacific Angiogenesis Inhibitors Market	113
Exhibit 28. Angiogenesis Inhibitors - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million	113
Exhibit 29. Angiogenesis Inhibitors – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific	114
3.9.1.4 (I) Japanese Angiogenesis Inhibitors Market	114
3.9.1.4 (II) Chinese Angiogenesis Inhibitors Market	114
3.9.1.4 (III) Australian Angiogenesis Inhibitors Market	114
3.9.1.4 (IV) India Angiogenesis Inhibitors Market	114
3.9.5 Rest of World Angiogenesis Inhibitors Market	115
Exhibit 30. Angiogenesis Inhibitors - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other Countries in US$ Million	115
Exhibit 31. Angiogenesis Inhibitors – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other Countries	116
3.9.1.5 (I) Brazilian Angiogenesis Inhibitors Market	116
3.9.1.5 (II) South African Angiogenesis Inhibitors Market	116
3.9.1.5 (III) Israeli Angiogenesis Inhibitors Market	116
3.9.2 Angiogenesis Stimulators	117
3.9.2.1 Global Angiogenesis Stimulators Market	117
Exhibit 32. Angiogenesis Stimulators - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	118
Exhibit 33. Angiogenesis Stimulators – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	119
3.9.2.2 North American Angiogenesis Stimulators Market	120
Exhibit 34. Angiogenesis Stimulators – North American Market Estimations & Predictions (2005 - 2020) by Country for United States and Canada in US$ Million	120
Exhibit 35. Angiogenesis Stimulators – North American Market Shares (2010, 2015 & 2020) by Country for United States and Canada	121
3.9.2.2 (I) United States Angiogenesis Stimulators Market	121
3.9.2.2 (II) Canadian Angiogenesis Stimulators Market	121
3.9.2.3 European Angiogenesis Stimulators Market	122
Exhibit 36. Angiogenesis Stimulators - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe in US$ Million	122
Exhibit 37. Angiogenesis Stimulators – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, France, Switzerland, Russia and Rest of Europe	123
3.9.2.3 (I) German Angiogenesis Stimulators Market	123
3.9.2.3 (II) UK Angiogenesis Stimulators Market	123
3.9.2.3 (III) French Angiogenesis Stimulators Market	123
3.9.2.3 (IV) Swiss Angiogenesis Stimulators Market	123
3.9.2.3 (V) Russian Angiogenesis Stimulators Market	123
3.9.2.4 Asia-Pacific Angiogenesis Stimulators Market	124
Exhibit 38. Angiogenesis Stimulators - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific in US$ Million	124
Exhibit 39. Angiogenesis Stimulators – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Japan, China, Australia, India and Rest of Asia-Pacific	125
3.9.2.4 (I) Japanese Angiogenesis Stimulators Market	125
3.9.2.4 (II) Chinese Angiogenesis Stimulators Market	125
3.9.2.4 (III) Australian Angiogenesis Stimulators Market	125
3.9.2.4 (IV) Indian Angiogenesis Stimulators Market	125
3.9.2.5 Rest of World Angiogenesis Stimulators Market	126
Exhibit 40. Angiogenesis Stimulators - Rest of World Market Estimations & Predictions (2005 - 2020) by Country for Brazil, South Africa, Israel and Other in US$ Million	126
Exhibit 41. Angiogenesis Stimulators – Rest of World Market Shares (2010, 2015 & 2020) by Country for Brazil, South Africa, Israel and Other	127
3.9.2.5 (I) Brazilian Angiogenesis Stimulators Market	127
3.9.2.5 (II) South African Angiogenesis Stimulators Market	127
3.9.2.5 (III) Israeli Angiogenesis Stimulators Market	127
3.10 Analysis by Therapeutic Area	128
Exhibit 42. Angiogenesis Therapeutic Areas - Global Market Estimations & Predictions (2005 - 2020) for Cancer, Cardiovascular, Ophthalmology and Other in US$ Million	128
Exhibit 43. Angiogenesis Therapeutic Areas – Global Market Shares (2010, 2015 & 2020) for Cancer, Cardiovascular, Ophthalmology and Other	129
3.10.1 Cancer Angiogenesis Modulators	130
3.10.1.1 Global Cancer Angiogenesis Modulators Market	130
Exhibit 44. Cancer Angiogenesis Modulators – Global Value Market Estimations & Predictions (2005 - 2020) by Cancer Therapeutics for Lung Cancer, Colorectal Cancer, Breast Cancer and Other in US$ Million	130
Exhibit 45. Angiogenesis Modulators for Cancer – Global Value Market Shares (2010, 2015 & 2020) by Cancer Therapeutics for Lung Cancer, Colorectal Cancer, Breast Cancer and Other	131
Cancer	132
Exhibit 46. Angiogenesis Cancer - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	133
Exhibit 47. Angiogenesis Modulators for Cancer – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	134
3.10.1.1 (I) North American Cancer Angiogenesis Modulators Market	134
3.10.1.1 (II) European Cancer Angiogenesis Modulators Market	134
3.10.1.1 (III) Asia-Pacific Cancer Angiogenesis Modulators Market	134
3.10.1.1 (IV) Rest of World Cancer Angiogenesis Modulators Market	134
3.10.2 Cardiovascular Angiogenesis Modulators	135
3.10.2.1 Global Cardiovascular Angiogenesis Modulators Market	136
Exhibit 48. Angiogenesis Modulators for Cardiovascular Diseases - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	136
Exhibit 49. Angiogenesis Modulators for Cardiovascular Diseases – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	137
3.10.2.1 (I) North American Cardiovascular Angiogenesis Modulators Market	137
3.10.2.1 (II) European Cardiovascular Angiogenesis Modulators Market	137
3.10.2.1 (III) Asia-Pacific Cardiovascular Angiogenesis Modulators Market	137
3.10.2.1 (IV) Rest of World Cardiovascular Angiogenesis Modulators Market	137
3.10.3 Ophthalmology Angiogenesis Modulators	138
3.10.3.1 Global Ophthalmology Angiogenesis Modulators Market	139
Exhibit 50. Angiogenesis Modulators for Ophthalmology - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	139
Exhibit 51. Angiogenesis Modulators for Ophthalmology – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	140
3.10.3.1 (I) North American Ophthalmology Angiogenesis Modulators Market	140
3.10.3.1 (II) European Ophthalmology Angiogenesis Modulators Market	140
3.10.3.1 (III) Asia-Pacific Ophthalmology Angiogenesis Modulators Market	140
3.10.3.1 (IV) Rest of World Ophthalmology Angiogenesis Modulators Market	140
3.10.4 Angiogenesis Modulators for Other Diseases	141
3.10.4.1 Global Market for Angiogenesis Modulators for Other Diseases	141
Exhibit 52. Angiogenesis Modulators for Other Angiogenesis based Diseases - Global Market Estimations & Predictions (2005 -2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	141
Exhibit 53. Angiogenesis Modulators for Other Angiogenesis based Diseases – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	142
3.11 Angiogenesis Modulators – Market Outlook	143
4. PRODUCT/TECHNOLOGY RESEARCH	144
4.1 Introduction	144
Angiogenesis – The Growth of New Blood Vessels	144
The Process	145
The Types	145
Sprouting Angiogenesis	145
Role of Angioprotien in Sprouting of Angiogenesis	146
Intussusceptive Angiogenesis	146
Role of Intussusceptive Angiogenesis in Embryonic Vascular Network Configuration	146
Therapeutic Angiogenesis	147
Role of Therapeutic Angiogenesis in Various Diseases	147
Delivery of Drugs in Cancer Therapy through Angiogenesis	148
Angiogenic Therapy for Heart	148
4.2 Modulators of Angiogenesis	148
Angiogenesis Inhibitors	149
Natural Angiogenesis Inhibitors	149
Angiostatin – A Potent Angiogenesis Inhibitor of Tumor Growth	149
Heparin Hexasaccharide Fragment	149
Interleukin-12	150
Placental Ribonuclease Inhibitor	150
Retinoids	151
Thrombospondin-1 (TSP-1)	151
Role of TSP-1 as Autocrine Negative Regulator for Human Dendritic Cell Activation	152
Cartilage Derived Inhibitor	152
Angioarrestin	152
Endostatin	153
Platelet Factor-4	153
Metalloproteinase Inhibitors	153
Interferon Alpha/Beta/Gamma	154
Other	154
Angiogenesis Stimulators	155
Natural Angiogenic Stimulators	155
Vascular Endothelial Growth Factor (VEGF)	155
VEGF Splice Variants and Their Functions	155
Role of VEGF in Various Diseases	155
Effect of VEGF & bFGF on In-vivo and In-vitro Conditions	156
Fibroblast Growth Factors	156
Basic FGF	157
Expression of bFGF (FGF2) in Various Diseases	157
Alzheimer's	157
Precursor Neural Cells of Mice	158
Acidic FGF	158
Role of aFGF in ADPKD	158
Expression of aFGF in Alzheimer's	159
Granulocyte Colony-Stimulating Factor (G-CSF)	159
Impact of G-CSF on Neutrophils	159
The Usage of G-CSF in Pharma Industry	159
Angiogenin	160
Angiopoietin-1	160
Platelet Derived Endothelial Cell Growth Factor	161
Uterine Cervical Cancers and Role of PD-ECGF	161
Leptin	161
Leptin’s MoA	162
Midkine	162
Placental Growth Factor	162
Stimulation of Inflammation and Swelling – Role of Placental Growth Factor	163
Hepatocyte Growth Factor (HGF)/Scatter Factor (SF)	163
Transforming Growth Factor (TGF)	164
TGFα	164
TGFβ	164
The TGFβ receptor	164
Other	164
4.3 Angiogenesis in Diseases	165
Remedy of Diseases with Angiogenesis Inhibitors	165
Angiogenesis Inhibitors-Patients Demographics	165
Exhibit 54. Angiogenesis Inhibitors - Global Market Estimations & Predictions (2005 -2020) of Patients Treated in Million	166
Cancer Therapy – Role of Angiogenesis	167
Global Market for Major Cancer Types	167
Exhibit 55. Global Market for Major Cancer Types (2010 & 2012) – Breast, Colorectal, Lung and Prostate in US$ Billion	167
Cancer Therapy Angiogenesis Vs Conventional	168
Conventional Cancer Treatments	168
Surgery	168
Radiation Therapy for Healing Cancer	168
Chemotherapy Treatment	169
Hormone Stimulation Therapy	169
Process of Immuno Therapy	169
Experimenting Phase	169
Targeted Therapy	170
Angiostatic Therapy	170
Angiostatic Agents	171
Angiolytic Photodynamic Therapy	172
Researches in Development of Cancer Therapy	173
Angiobalans	174
Global Cancer Demographics	175
Exhibit 56. Global Cancer Incidence – Estimated Incidence and Mortality for 2012 in Thousands	175
Alzheimer’s	175
Dermatology	176
Cosmetic Dermatology	176
Angiogenesis in Dermatology	176
Angiogenesis Inhibitors	176
Angiogenesis Stimulating Drugs	176
Psoriasis	176
Role of Angiogenesis in Psoriasis	177
Rosacea	177
MoA of Photoaging in Rosacea Pathogenesis	178
Ophthalmology	178
Age Related Macular Degeneration	178
Advanced stage of vision loss	178
Causes	179
Characteristics of the Disorder	179
Detection process of the Disorder	180
Medication	180
Precautionary measure	180
Types of AMD	181
Other Turmoil Based on Angiogenesis	181
Rubeosis Iridis	181
Neovascularization	181
Neovascularization in Association with Angiogenesis	182
Rheumatology	182
Rheumatoid Arthritis	182
Angiogenesis in Rheumatoid Arthritis – Pathogenic and Therapeutic Implications	183
Skin Related Ailments	183
Deficient Angiogenesis in Skin Diseases	183
Osteoarthritis (OA), Angiogenesis and Inflammation	184
Other	184
Inflammatory Diseases	184
Growth of New Blood Vessels in Inflammation	184
Cause of joint swelling due to inflammation	185
Endometriosis	186
Symptoms of the Disease	186
Wound Care – Role of Angiogenesis	187
Soluble Factors Responsible for Wound Angiogenesis	188
Diabetic Foot Ulcers	188
Angiogenesis in Cardiovascular Disorders	189
Ischemia	190
Role of ASK 1 in Angiogenesis during Ischemia	190
Role of NGF in Neo-Vascularization during Ischemic Conditions	190
Congestive Heart Failure	190
Root of CHF	191
Detection of CHF	191
Treatment of CHF	191
Role of Angiogenesis in CHF	192
Coronary Artery Disease	192
Angina	192
Heart Attack	192
Heart Failures	192
Arrhythmias	192
Symptoms Identified for CAD	193
Role of Angiogenesis in CAD Treatment	193
Peripheral Vascular Disease	193
Angiogenic Therapy for the Treatment of PVD	194
Peripheral Artery Disease	194
Therapeutic Angiogenesis in PAD	194
Myocardial Infarction	195
4.4 Angiogenesis Modulators - Research Briefs	196
Model of MicroRNAs in Liver Cancer for Studying Pathogenesis and New Therapeutic Methods	196
Doctors Develop Personalized Cancer Treatments with Help of Novel Research Technique	196
Work by a Bangalorean, May Make Bypass Outdated	197
Scientists Find a Natural Retinal Neovascular Mouse Prototype	198
Tumor Characteristic of Taking Control Over Brain's Blood Supply Could Help in Treatment	199
Protein Blocking Tumor Growth, found	201
Cutting Off Nutrients to Pancreatic Cancer Cells	201
Omega (ω)-3 Blocks Blood Vessel Growth in AMD	202
Scripps Research Institute Researchers Show Molecular ‘Yin-Yang’ of Blood Vessel Growth	203
Molecules Identified that Act in Rheumatoid Arthritis Angiogenesis	204
Presence of Marker May Predict Response to Ipilimumab in Advanced Melanoma	205
Combinatorial Drug Therapy for Triple-Negative Breast Cancer	206
Recent Variety Discovered Immune Cell that Enable Tumors to Grow	207
Methylation Signaling Regulates Cancer Growth	207
Ramucirumab Prolongs Longevity in Stomach cancer	208
Proteins Concerned with Spread of Brain Tumors Found	208
Novel MR Analysis Procedure Discloses Brain Tumor Reaction to Anti-angiogenesis Therapy	209
Molecule of Immune System Favors Tumor Resistance in Anti-angiogenic Therapy	210
New Target to Fight against Angiogenesis based Cancer	210
Synergistic Therapy for Ovarian Cancer	211
Latest Two-Drug Combination Aids Ovarian Cancer Treatment	212
Protein Concerned with ‘Bad’ Blood Vessel Growth Found	212
Genetic Variants Indicating Aggressive Prostate Cancers Found	213
Cholesterol May Cause Unregulated Growth of Blood Vessels	214
Study Reveals Enzyme’s Double Life and Its Important Part in Cancer Blood Supply	214
Fatty Acid Metabolite Found to be Useful to Fight Cancer in Mice	215
Drug Decreases Fats by Blocking Blood Vessels	216
Reprieve for Gynecological Disorders: An Injectable Protein That Could Undo Symptoms of Dangerous Conditions	217
Spread of Skin Cancer to Other Parts of the Body	218
Discovery of New Protein that Can Treat Damaged Bones	219
Investigation Provides New Targets for Stroke Therapy	219
Combination Therapy May Help Improve Chances of Survival of the Patients of Breast Cancer with Brain Metastases	220
Simvastatin, if Applied Topically Can Expedite Healing of Diabetic Wounds	221
New Blood –Vessel Generating Cell with Treatment Capacity	222
Double Drug Combination Could Close Down Abnormal Blood Vessel Proliferation that Encourages Disease	223
New Subtypes of Ovarian Cancer May be Susceptible to Anti-Angiogenic Drugs	224
PDGF-BB and EPO in Cancer Cause	225
Hydrogel Aids in Scar-Free Skin in Third-Degree Burn	226
Cell Molecule Identified as Central Player in the Formation of New Blood Vessels	227
Identification of Key Molecule Blocking Abnormal Blood Vessel Growth in Tumors	229
Dual-Action Protein Performance in Controlled Blood Vessel Formation	230
Novel Understanding into the Way Tumor Cells are Fed	231
Mechanism behind Cancer Growth by White Blood Cell Discovered	233
Blocking Receptor in Key Hormone Aids in Cancer Cell Death	234
Exorbitant Blood Vessels Leads to Alzheimer’s Disease	235
Gold Nanoparticles Help Scientists in Getting a Step Closer to Treatment for Cancer	237
Immune System Suppression Has Been Linked to Blood Vessel Formation in Tumors	238
Indirubin May Block Brain Tumor's Spread	239
New Molecular Imaging Agent for Detection of Angiogenesis	240
A New Imaging Agent for Detection of Breast Cancer	241
Regenerating Blood Vessels	241
Protein May be Able to Improve Recovery from Heart Attacks	242
Zoledronic Acid in the Treatment of Early Lung Cancer	243
DMP1 Protein May Lead to Cancer and Other Diseases	244
Protein That Diminishes Melanoma Tumor Growth, Discovered	244
Blocking Blood Vessels Two Times Leads to Tumor Starvation	245
ACE-041, Novel Target to Stop Tumor Blood Supply	245
nPT-bor Program – New Molecular Target	246
Enhancement in Radiation Therapy Discovered with New Targets for Available Drugs	246
New Anti-Angiogenesis Targets Discovered	247
EZH2 Aids in Creation of Blood Vessels for Ovarian Cancer	247
Cellular Mechanism and Blood Vessel Permeability	248
miR-132 and Uncontrolled Cell Growth	248
Advanced study shows Morphine’s Effectiveness on Blocking Tumor Growth	248
Gene Expression Targeting Angiogenesis	249
MR Imaging of Angiogenesis Using Nanosized Contrast Agents	249
Bone Marrow Cells Producing Nerve Growth Factors Promotes Angiogenesis	250
Angiogenesis can be Activated by the Cellular Mechanical Forces	251
Angiogenesis to be Monitored by HRGP	252
Blocking of EphB4 Obstructs Angiogenesis As Well As Tumor Growth	253
New Inhibitor of Tumor Angiogenesis	254
Obstructing Nuclear Receptor Cuts Off Tumor Blood Supply	254
New Target for Prospective Breakthrough in Cancer Treatment	255
Targeting of Cancerous Vessels	255
Probiotics Effective for Colitis Treatment	256
Mechanism Preventing Formation of Blood Vessels, Explained	256
Process of Metastasis in Prostate Cancer	256
Hearing Improved via Tumor Inducing Genetic Disorder Treatment	257
Discovery of SFRP2, a New Target to Aid in Potential Cancer Drug Development	258
Angiogenesis and Ovarian Cancer Drugs	258
Angiogenesis Inhibitor Enhances Brain Tumor Survival	259
New Compact Device for Restraining Production of Blood Vessels	260
Reducing Cholesterol May Reduce the Risk of Cancer	261
Novel Oral Therapy Aids in Lung Cancer Shrinking before Surgery	261
Angiogenesis Inhibitor Formulated Through Nanotechnology Shows Promising Anticancer Results	262
Anti-Cancer Synthetic Drug Candidate Targets Tumor Cell Growth and Angiogenesis	264
RGS5 Helps in Treating Tumors	264
Stem Cell Types a vital Constituent in Angiogenesis and Cancer Growth	265
Asthma Susceptibility Gene Causes Breathing Difficulties	266
Effect of Prokineticin 2/Bv8 on Human Hepatocellular Carcinoma	267
VEGF Family Protein Protect Nerve Cells from Death without Side Effects	268
Development of New Molecular Pathways which Demonstrate Development of New Blood Vessels	268
New Protein Drug Target Discovered, that Controls Blood Vessel Formation	269
Specific Manipulation of Tumor Angiogenesis Gene	270
Infertility Treatment for Women Discovered	270
Blocking Angiogenesis Signaling From Inside Cell May Lead to Serious Health Issues	271
New Ways for Endometriosis Treatment	273
Targeting Heparan Sulfate Inhibits Cancer Growth	274
Antifungal Drug Stops Blood Vessel Growth	274
Endorepellin and its Role in Halting Blood Vessels from Forming in Cancer	275
New Angiogenesis Discovery May Facilitate Fight against Cancer Growth	276
Cancer Stem Cells and Brain Tumor Therapy	278
MicroRNAs and Angiogenesis	278
V. CORPORATE DIRECTORY	280
VI. PATENTS INFORMATION	311

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $5400
Multi User - US $9100
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify